Companies to Focus on Therapeutic Targets Showing Cause and Effect

Aitia has been featured in Huntington’s Disease News for its collaboration with UCB to develop a new treatment for Huntington’s disease. The article highlights Aitia’s expertise in Causal AI as “a new branch of artificial intelligence that goes beyond establishing links between variables: It makes decisions and predictions based on cause and effect.” The collaboration […]

UCB Enters Drug Discovery Collaboration with Aitia

Aitia latest strategic drug discovery collaboration with UCB, focused on the discovery and validation of novel drug targets and drug candidates for Huntington’s disease. The collaboration will combine the use of new drug targets for Huntington’s disease from Aitia’s Gemini Digital Twins with the expertise of UCB in preclinical model systems and drug research in neurodegeneration for advancing […]